Meissa Vaccines is focused on the advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (the leading cause of infectious disease worldwide). The technology is sourced from Dr. Martin Moore's laboratory at Emory University. Dr. Moore, together with Dr. Roderick Tang, a leading developer of viral vaccines, are co-founders of Meissa. They are supported by a team with extensive experience in conducting vaccine clinical trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/04/17 | undisclosed | Seed | ||
| 09/27/19 | $30,000,000 | Series A |
Morningside Group | undisclosed |
